Clinical Trials · NCT05209165
Semaglutide to Reduce Atrial Fibrillation Burden
- Phase
- Phase 4
- Recruitment status
- Suspended
- Sponsor
- San Francisco Veterans Affairs Medical Center
- Enrollment
- 132
- Start date
- May 2023
- Locations
- 1 site, United States
- Primary endpoint
- Atrial fibrillation burden